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Dendritic cells (DCs) as highly efficient antigen-presenting cells are at the interface of 
innate and adaptive immunity. As such, they are key mediators of immunity and antigen- 
specific immune tolerance. Due to their functional specialization, research efforts have 
focused on the characterization of DCs subsets involved in the initiation of immunogenic 
responses and in the maintenance of tissue homeostasis. Tolerogenic DCs (tolDCs)-
based therapies have been designed as promising strategies to prevent and control 
autoimmune diseases as well as allograft rejection after solid organ transplantation 
(SOT). Despite successful experimental studies and ongoing phase I/II clinical trials 
using autologous tolDCs in patients with type 1 diabetes, rheumatoid arthritis, multiple 
sclerosis, and in SOT recipients, additional basic research will be required to determine 
the optimal DC subset(s) and conditioning regimens for tolDCs-based treatments in vivo. 
In this review, we discuss the characteristics of human DCs and recent advances in their 
classification, as well as the role of DCs in immune regulation and their susceptibility to 
in vitro or in vivo manipulation for the development of tolerogenic therapies, with a focus 
on the potential of tolDCs for the treatment of autoimmune diseases and the prevention 
of allograft rejection after SOT.
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iNTRODUCTiON
Dendritic cells (DCs) are at the interface of innate and adaptive immunity and, thus, are key 
mediators of immunity and tolerance. Importantly, DCs constitute a heterogeneous population 
that comprises multiple subsets exhibiting distinct functional specializations that vary according 
to their origin, maturation state, location, and environmental conditions (1, 2). In their immature 
state, DCs mainly traffic and reside in peripheral tissues where they can capture antigens and 
process them into major histocompatibility complex (MHC):peptide complexes. DCs undergo 
maturation not only after microbial infection but also in response to damage-associated molecular 
patterns (DAMPs) and pro-inflammatory cytokines produced as a result of tissue injury. This is the 
cornerstone for the initiation of effective adaptive immune responses (3, 4). Extensive experimental 
data over the years have highlighted the possibility of generating “tolerogenic DCs” (tolDCs) that 
are maturation-resistant in vitro, express low levels of T-cell costimulatory molecules, and a have a 
Table 1 | Characteristics of blood human dendritic cells (DCs) and monocyte-derived DCs (ModDCs) subsets.
CD1c CD141 Plasmacytoid DCs (pDCs) ModDCs Reference
Surface expression, 
intracellular markers 
or transcriptional 
markers
Lin−, MHC II+
CD1c+ (BDCA-1+)
CD11chi, CD11b−
CD4+, CD2+
CD45RO+
CD172α+
IRF4+
Lin−, MHC II+
CD141hi (BDCA-3hi/
Thrombomodulin)
CD11c+,CD11b−
CD4+, CD2−
TLR3+
Clec9A+ (DNGR-1+)
XCR1+
IRF8+
Lin−, MHC II+
CD303+ (BDCA-2+)
CD304+ (BDCA-4+/
Neuropilin-1)
CD11c−, CD11b−
CD123+
CD45RA
CD4+
ILT7+
TLR7+, TLR9+
CD1c+ (BDCA-1+)
CD14+
CD11c+, CD11b+
DC-SIGN+
Additional markers expressed in tissue 
ModDCs:
CD1a+
CD206+
FcεRI+
FLT3+
IRF4+
Zbtb46+
(6–17)
Frequency in 
peripheral blood
(% peripheral blood 
mononuclear cell)
0.2 ± 0.1% 0.02 ± 0.01% 0.2 ± 0.1% ≈0.29 ± 0.2% (18, 19)
Functional 
specialization
Excel in CD4+ T-cell 
priming.
Th1 and Th17 
polarization.
Cross-presentation of soluble 
antigens to CD8+ T cells.
Secretion of Type-I IFN (poly I:C)
Type-I IFN secretion in 
response to viral infections.
Liver and respiratory tract 
pDCs promote tolerance.
Naïve and memory CD4+ T-cell 
stimulation.
Th17 polarization.
DC-10, skin CD141+CD14+ DCs and 
CD1c+CD14+ DCs in melanoma patients 
promote tolerance.
(6, 9, 20, 21)
Mouse equivalent CD4+, CD11b+ 
(lymphoids)
CD11b+ (tissues)
CD172α+
IRF4+
CD8α DCs (lymphoids)
CD103 DCs (tissues)
XCR1+
IRF8+
B220
Siglec H
BST2 (PDCA1)
Ly6C+
CD172α+
DC-SIGN+
CD206+
FcεRI+
(7, 22, 23)
BDCA, blood dendritic cells antigen; DNGR-1, dendritic cell natural killer lectin group receptor-1; IFN, interferon; ILT, immunoglobulin-like transcript; Lin, lineage; MHC II, major 
histocompatibilty complex class II; TLR, toll-like receptor.
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reduced capacity to produce pro-inflammatory cytokines. These 
tolDCs mediate antigen-specific T-cell hyporesponsiveness and 
promote the expansion and/or induction of regulatory T cells 
(Treg). Thus, the potential for tolDCs to dampen immune 
responses may be used clinically, e.g., in autoimmune diseases 
and after solid organ transplantation (SOT). In this review, we 
briefly describe human DC subsets and the immune regulatory 
mechanisms mediated by these cells. We then discuss how DCs 
may be manipulated in the perspective of tolerogenic immune 
therapies.
HUMaN DC SUbSeTS aND FUNCTiONal 
SPeCialiZaTiON
Dendritic cells represent a heterogeneous cell population aris-
ing from bone marrow-restricted precursors identified in mice 
and humans (5). In humans, common DC progenitors give rise 
to plasmacytoid DCs (pDCs) and intermediate precursors of 
conventional DCs (pre-cDCs) that are pre-committed to become 
either CD1c+ (BDCA-1) or CD141+ (BDCA-3) conventional DCs 
(cDCs) (6). The HLA-DR+CD14−CD11b− fraction of human 
peripheral blood mononuclear cells (PBMCs) comprises the 
CD1c+ DC subset (characterized by CD172α and IRF4 expres-
sion), the CD141high DC subset (characterized by Clec9A, XCR1, 
IRF8, and TLR3 expression), and the pDC subset (identified by 
BDCA-2, BDCA-4, and CD123bright expression) (Table 1).
Peripheral blood DCs
Peripheral blood DCs are likely the precursors of DCs found in 
peripheral tissues and lymphoid organs. In peripheral tissues, 
there is evidence for high phenotypic heterogeneity of DCs, 
contrasting with the well-defined phenotypic expression of blood 
DCs. In addition to the BDCA population and Langerhans cells, 
other subpopulations of tissue DCs can be distinguished by 
the expression of langerin, CD1a, and CD14 (24, 25); however, 
these markers are promiscuously expressed making it difficult to 
unambiguously discriminate peripheral tissue DC subpopulations 
(24). For example, studies in patients with allergic asthma show 
that most of the lung CD1c+ (BDCA-1+) DCs also express CD141 
(BDCA-3) (26). Recently, using gene expression profiling and 
mass cytometry analysis, a set of lineage-imprinted cell-surface 
markers, such as CD172α/IRF4 and XCR1/IRF8, were identified, 
allowing for a better discrimination between CD1c+CD14− DC 
and CD141+CD14− DC subsets in human tissues (7).
lymphoid Organs DCs
Multiple subsets of DCs have been found in lymphoid organs; 
however the distinction between migratory and lymphoid organs-
resident DCs still requires further investigation. CD1c+CD14− 
DC, CD141+CD14− DC, and pDC subsets have been found in the 
human spleen, tonsils, and axillary and pulmonary lymph nodes 
(LNs) (8–10, 27). These subsets likely correspond to the resident 
DC population. In axillary LNs, pDCs have been reported to 
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localize in the paracortex (27). The CD141+CD14− DC subset, 
characterized by Clec9A expression, is mostly distributed around 
the LN cortex (inner and outer) (25). By contrast, CD1c+CD14− 
DCs have been reported to localize within the T-cell zone in 
close proximity to the B-cell zone (10). Interestingly, in axillary 
and pulmonary LNs, but not in the spleen and tonsils, a high 
frequency of a HLA-DR+ cells with the CD141+CD14+DC-
SIGN+CD206+CD1c+CCR7int/low phenotype has been reported, 
suggesting that this subset could be related to a migratory subset. 
This population is found in the diffuse T-lymphocyte regions of 
the LN paracortex (10, 27).
Monocyte-Derived DCs (ModDCs)
In vitro experiments have documented that monocytes are 
important precursors of DCs (28, 29). However, it has been 
difficult to properly identify ModDCs in  vivo due to common 
features shared by cDCs, monocytes and macrophages. Recent 
data suggest that a ModDCs subset may exist in humans (10–12, 
25, 30). For example, studies in steady-state conditions described 
a subpopulation of cells expressing CD1c+CD14+HLA-DR+ in 
both blood and bronchoalveolar lavage fluid (BALF) (10, 18). 
Although it was demonstrated that blood CD1c+CD14+ cells 
have monocytic features, these cells have increased antigen-
presenting ability and a different gene signature compared 
to monocytes (18). Interestingly, in non-diseased lung tissue 
CD1c+CD14+ populations were shown to be enriched for the 
gene signatures of ModDCs described in the literature, which 
includes the expression of ZBTB46, IRF4, and FLT3 genes (10). 
During inflammation, CD1c+CD14+ cells have been reported 
in the BALF from sarcoidosis patients co-expressing CD141, 
CD123, and DC-SIGN, or in synovial fluid from rheumatoid 
arthritis (RA) patients and carcinomatous ascites from untreated 
cancer patients co-expressing CD1a, FcεRI, CD172a, and CD206 
(11, 12). These cells were enriched for the ModDC signature and 
functionally ModDC from ascites showed an important capacity 
to polarize naive T  cells into Th17  cells as well as to stimulate 
memory CD4 T cells to produce IL-17 (11).
In the past few years, additional DC subsets were associ-
ated with the induction of immune tolerance; however, their 
precise ontogeny and phenotype remains to be fully established. 
Gregory and co-workers described a DC subset expressing HLA-
DR+CD14+CD16+ receptors in human blood, which was able to 
induce type 1 regulatory T (Tr1) cells through the release of IL-10; 
hence, its name DC-10 (31). Furthermore, the presence of a DC 
subset expressing HLA-DR+CD141+CD14+ was reported in skin 
dermis. This subset exhibited a potent inhibitory activity on skin 
inflammation.
Functional Specialization of DCs
In terms of function, DCs can exhibit an immature phenotype at 
steady-state or a mature phenotype upon exposure to inflamma-
tory stimuli. Immature DCs have a unique immune surveillance 
function. At this stage, DCs express low levels of MHC and 
costimulatory molecules such as CD80/B7.1, CD86/B7.2, CD40, 
OX40L, inducible T-cell costimulatory ligand, as well as low 
expression of adhesion molecules such as intercellular adhesion 
molecule-1 (ICAM-1/CD54) (32). Interestingly, at steady-state 
tissue CD1c+CD14− DCs exhibit a higher activation state, e.g., 
higher expression levels of CD80, CD83, CD86, and CD40 com-
pared with their blood counterparts (22, 30).
Quiescent immature DCs can mature and become activated 
in local tissues in the presence of pathogen-associated molecular 
patterns or DAMPs in the context of sterile injury (e.g., auto-
immunity or ischemia/reperfusion) and local inflammatory 
mediators (IFN-α, IL-1β, IL-6, TNF-α, or CD40L/CD154). 
Within the context of this maturation process, DC function is 
regulated by a core set of genes controlled by NF-κB and IFN-
mediated signaling (33). In this process, immature DCs evolve 
from an antigen-capturing mode to an antigen-processing and 
antigen-presenting mode by upregulating MHC molecules and 
costimulatory molecules along with chemokine receptors. This 
allows them to migrate to specialized lymphoid organs, release 
the corresponding polarizing cytokines, and initiate specific 
adaptive immune responses.
Regarding the fate and function of human DCs, both unsti-
mulated CD1c+CD14− and CD141+CD14− DCs from blood, 
non-lymphoid, and lymphoid tissues were shown to be more 
immunogenic than pDCs, with an increased capacity to process 
and present soluble foreign antigens, including transplant-
derived alloantigens, as immunogenic MHC:peptide complexes 
to CD4+ T cells (25, 34–36). It has been reported that both blood 
CD1c+ DCs and CD141+ DCs efficiently induce Th1 polarization 
in allogeneic co-culture assays, the latter with increased release 
of IFN-γ upon maturation (9). CD141+ DCs were also shown to 
be more efficient at inducing Th2 cells compared to CD1c+ DCs 
(20). By contrast, both CD1c+ and CD141+ DCs derived from 
lymphoid tissues efficiently induced Th1 and Th2 responses (21). 
In lung tissues, CD1c+ DCs were shown to have a great capacity 
to induce Th17 responses following A. fumigatus challenge (37). 
In addition to their capacity to induce effector CD4+ T cells, all 
DC subsets isolated from lymphoid tissues were able to efficiently 
cross-present soluble antigens to CD8+ T  lymphocytes (21). 
CD141+ DCs are referred to as “human cross-presenting DCs” 
due to their functional homology with mouse CD8α+ DCs 
(38, 39), in particular with respect to the expression of TLR3 
which promotes cross-priming and is required for the production 
of large amounts of IFN-λ upon TLR3 ligation (13).
In comparison to cDCs, pDCs have a similar distribution in 
peripheral blood and lymphoid organs, but are present at lower 
numbers in tissues (30, 40). In the immature state, pDCs express 
lower levels of costimulatory molecules but multiple pattern 
recognition receptors that are important for type-I IFN secretion, 
including intracellular TLR7 and TLR9 (14). In the presence of 
infectious or inflammatory stimuli, pDCs traffic to lymphoid 
organs and sites of inflammation. While their role was first 
described in response to viral infections via the recognition of 
nucleic acids, tissue-resident gut and airway pDCs have been shown 
to exert a pivotal role in oral and mucosal tolerance (15, 16, 41). 
In experimental mouse models of SOT as well as in clinical liver 
transplantation, pDCs were associated with the generation of 
alloantigen-specific Treg promoting prolonged allograft survival 
(42–45). Activated pDCs could also induce CD8+ Treg in in vitro 
co-cultures (46).
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Overall, these studies highlight the diverse responses of DCs 
depending on their origin. Bona fide cDC were demonstrated 
to have an inherent capacity to induce immunogenic responses, 
while pDCs and some immature ModDC subsets participate in 
tolerance induction. In humans, however, the functional spe-
cialization of DCs in the polarization of T cells appears to be less 
sharply defined compared to mice. The nature and the intensity 
of the stimuli, as well as the local environment, play an important 
role in determining the functional specialization of human DCs.
MeCHaNiSMS OF iMMUNe  
ReGUlaTiON bY DCs
Dendritic cells play an important role in the maintenance of 
immune homeostasis and self-tolerance under steady-state con-
ditions. Their significant role in the induction and maintenance 
of tolerance has been demonstrated in experimental models. 
Constitutive or conditional depletion of cDCs was shown to break 
self-tolerance of CD4+ T cells, leading to spontaneous develop-
ment of lethal autoimmunity manifested by splenomegaly, neu-
trophilia, autoantibody formation, and an increased frequency of 
Th1 and Th17 effector cells (47, 48).
Surface Molecules expressed on tolDCs
In the absence of local inflammation, DCs remain immature with 
low surface expression of MHC class II and costimulatory mol-
ecules, reflecting their participation in the maintenance of periph-
eral immune tolerance. Indeed, some DC subsets, such as CD103+ 
DCs in mice and pDCs, blood DC-10, and skin CD141+CD14+ 
DCs in human, exhibit inherent tolerogenic properties including 
the ability to induce Treg and/or promote T-cell hyporespon-
sivness to antigenic stimuli (15, 31, 49, 50). In addition to low 
expression of MHC class II and costimulatory molecules, tolDCs 
overexpress inhibitory molecules such as HLA-G, programmed 
death ligand (PD-L)-1 and PD-L2, and galectins that contribute 
to their tolerogenic potential. HLA-G is a non-classical MHC 
class I antigen that plays an important role in materno-fetal toler-
ance. Through interactions with inhibitory receptors expressed 
on maternal NK cells (killer cell immunoglobulin-like receptor, 
KIR) and T cells (ILT2 and ILT4), the expression of HLA-G on 
fetal cells protects them against maternal alloreactive cytotoxic 
cells (51). HLA-G engagement of the human inhibitory receptor 
ILT4 overexpressed on DCs in transgenic mice promoted long-
term survival of allogeneic skin grafts, in part as a result of the 
downregulation of MHC class II and costimulatory molecules, 
leading to the induction of Treg and hyporesponsiveness of the 
alloreactive T-cell repertoire (52). Expression levels of PD-L1 and 
PD-L2 on DCs increase during DC maturation. These ligands can 
interact with the inhibitory receptor PD-1 expressed on activated 
T  cells and Treg, thus contributing to T-cell homeostasis (53). 
Galectins have been identified as important regulators of T cells 
and DCs (54–56). Galectin-1 was shown to inhibit T-cell effector 
functions by promoting growth arrest and apoptosis of activated 
T  cells (57, 58), and by blocking pro-inflammatory cytokines 
secretion by DCs (59). Moreover, galectins are overexpressed 
in the microenvironment of tumors and have been implicated 
in their immune escape. In in  vivo models, DCs constitutively 
expressing galectin-1 delayed the onset of autoimmune diabetes 
in mice (60). Conversely, galectin-1-deficient mice experienced 
accelerated rejection of skin allografts (61).
immunomodulatory Molecules Secreted 
by tolDCs
Tolerogenic DCs were shown to secrete molecules, such as trans-
forming growth factor-beta (TGF-β), IL-10, and indoleamine 
2,3-dioxygenase (IDO), which favor a tolerogenic environ-
ment and the induction and/or expansion of Treg. TGF-β is a 
pleiotrophic cytokine involved in multiple cellular functions, 
including growth, differentiation, proliferation, remodeling, 
apoptosis, and immune homeostasis. TGF-β is secreted in a 
latent form complexed with latent TGF-β binding protein and 
latency-associated peptide. tolDCs were shown to play a crucial 
role in both the release of TGF-β and activation of the latent 
TGF-β protein complex (62, 63). TGF-β has been also involved 
in the induction of Foxp3 expression and peripheral conversion 
of conventional naïve CD4+ T cells into induced Treg (iTreg) in 
the presence of IL-2 (64, 65). Through their constitutively high 
expression of the inhibitory receptor cytotoxic T-lymphocyte 
antigen-4 (CTLA-4/CD152), Foxp3+ Treg ligate B7.1/2 expressed 
on mature DCs and outcompete costimulatory CD28 unregulated 
on effector T  cells (Teff) (66). The interaction between B7.1/2 
and CTLA-4 was shown to promote the expression of IDO by 
DCs, a potent regulatory molecule that catalyzes the degradation 
of tryptophan required for Teff functions (67–72). In addition, 
tryptophan catabolites, such as kynurenine, quinolinic acid, and 
3-hydroxyanthranilic acid exhibit direct immunosuppressive 
properties (73, 74).
Function of tolDCs
Mouse CD103+ DCs as well as both human and mouse pDCs 
were shown to mediate oral tolerance through an IDO-dependent 
mechanism (49). In human blood, DC-10 induce and expand 
Tr1 cells through the release of IL-10 and TGF-β (31, 75). DC-10 
identified as CD11b+CD11c+CD14+CD16+CD83+HLA-DR+ 
cells that do not express CD1a and CD1c. Furthermore, DC-10 
expresses the inhibitory receptors ILT2, ILT3, ILT4, and HLA-
G. Despite concomitant high surface levels of costimulatory 
molecules (CD40, CD80, and CD86), DC-10 exhibit potent 
tolerogenic activity (31). Another DC population characterized 
by CD1c+CD14+CD16− expression was found in the blood of 
melanoma patients and exhibited immunosuppressive functions 
by suppressing T-cell proliferation in an antigen-specific manner. 
It was suggested that this DC subtype modulated T-cell responses 
through the expression of PD-L1 (18). A similar phenotype was 
described in minced lung tissues. The frequency of the CD1c+ 
subset (including the CD1c+CD14+ fraction) was increased in 
patients with chronic obstructive pulmonary disease, suggesting 
that these cells may be involved in the enhanced susceptibility 
of these patients to infections. Indeed, this subset favored the 
generation of IL-10-secreting CD4+ T cells and mediated immu-
nosuppression through IL-10, IL-27, and ICOS-L (76). In skin 
dermis, resident CD141+CD14+ DCs were shown to produce 
large amounts of IL-10 and were able to induce Treg (50).
FiGURe 1 | Strategies to generate tolDCs for clinical therapeutics. PBMCs or bone marrow-derived cells can be differentiated into tolDCs in the presence of 
pharmacologic agents and immunomodulatory cytokines. The generated tolDCs are either donor-derived (in the case of living-donor transplantation) or autologous 
(in the case of autoimmune diseases or transplantation) and can be further pulsed in vitro with specific antigens (peptides, donor cell lysates, apoptotic cells). tolDCs 
can regulate Teff responses by various mechanisms: 1. Fas/FasL pathway-mediated deletion; 2. Production of IDO which degrades the essential amino acid 
tryptophan through kynurenine pathway, causing starvation of Teff. The production of IDO is favored by reversed signaling via interaction between CD80/CD86 on 
DCs and CTLA-4 on regulatory T cell (Treg). 3. Surface expression of inhibitory molecules and secretion of regulatory mediators. Abbreviations: CTLA-4, cytotoxic 
T-lymphocyte antigen-4; IDO, indoleamine 2,3-dioxygenase; iTreg, induced regulatory T cell; PBMC, peripheral blood mononuclear cells; tolDC, tolerogenic dendritic 
cell; Teff, effector T cell; Tmem, memory T cell; Tnaive, naïve T cell; tTreg, thymic-derived regulatory T cell.
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Besides their role in controlling peripheral immune responses, 
DCs play a role in the maintenance of central tolerance, as traf-
ficking peripheral DCs can home to the thymus and promote 
negative selection of antigen-reactive T cells, thus contributing to 
a safe peripheral T-cell repertoire (77, 78). By presenting antigens 
directly within the thymus, DCs and particularly resident pDCs 
influence the generation of natural Foxp3+ Treg, a process medi-
ated by the IL-7-related molecule, thymic stromal lymphopoietin 
(TSLP), which is secreted in the thymic medulla (79–81).
GeNeRaTiON OF tolDCs
Dendritic cell-based therapeutic approaches are being explored 
with the aim to reestablish self-tolerance in autoimmune diseases, 
and to promote alloimmune tolerance after SOT. Several strate-
gies for the generation of tolDCs are being explored (Figure 1). 
These include treatment with pharmacologic agents or cocktails of 
immunomodulatory cytokines, genetic engineering, and exposure 
to apoptotic cells. Research groups have developed protocols to 
generate and expand antigen-specific tolDCs in  vitro. Most of 
these in vitro conditioning regimens aim to stabilize the immature 
state of DCs, even in the presence of strong inflammatory chal-
lenges [e.g., lipopolysaccharide (LPS)]. The resulting tolDCs also 
express and/or secrete immunomodulatory molecules that favor 
the development and expansion of Treg (82, 83). After adoptive 
transfer in  vivo, maturation-resistant tolDCs may, therefore, 
promote peripheral tolerance mainly by inducing antigen-
specific T-cell hyporesponsiveness and an immuno-regulatory 
microenvironment.
Pharmacologic interventions  
for tolDC induction
Various pharmacological agents have been used to generate 
tolDCs, including immunosuppressive drugs, cyclic AMP induc-
ers, chemicals, cytokines, and growth factors (Table 2) (84, 85). 
Many of these agents were primarily studied for their inhibitory 
Table 2 | Pharmacologic interventions to induce tolerogenic DCs (tolDCs).
Therapeutic agents immunomodulatory substances
Immunosuppressive drugs CTLA-4 Ig (86)
Rapamycin (87), Cyclosporine A (88),  
Tacrolimus (89)
Mycophenolic acid formulations (90, 91)
Corticosteroids (92)
DSG analogs (93, 94)
Cyclic AMP inducers Prostaglandine E2 (95)
Histamine (96)
Chemicals Vitamin D3 (91, 97)
Aspirin (98–100)
Activator of the aryl hydrocarbon receptor (101)
Proteins and neuropeptides HLA-G (31, 52)
C4b-binding protein α7β0 isoform (102)
Vasoactive intestinal peptide (103–105)
α-melanocyte-stimulating hormone (106, 107)
Cytokines Low doses of GM-CSF without IL-4 (108)
IL-10
TGF
AMP, adenosine monophosphate; DSG, 15-deoxyspergualine; GM-CSF, granulocyte-
macrophage colony-stimulating factor; HLA, human leukocyte antigen; IL, interleukin; 
TGF, transforming growth factor-beta.
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effects on T-cell activation and proliferation. As such, some of 
them are currently used in the clinical treatment of autoimmune 
diseases and in the prevention of allograft rejection after SOT.
Dexamethasone, a potent immunosuppressant, blocks the 
differentiation and maturation of DCs and enhances their death 
by apoptosis (92, 109). Using rat bone marrow-derived DCs and 
human GM-CSF/IL-4-induced ModDCs, we demonstrated that 
pretreatment with dexamethasone-induced selective expansion 
of Treg and T-cell alloantigen-specific hyporesponsiveness in 
re-challenge experiments (110). Dexamethasone was reported 
to have synergistic effects with other drugs to induce tolDC, 
in particular 1,25-dihydroxyvitamin D3 (VitD3) (111). While 
traditionally known for its role in the regulation of calcium and 
bone homeostasis, VitD3 and its receptor were also described 
to regulate innate and adaptive immune responses. Exposure 
to VitD3 inhibited the expression of MHC class II, CD80, 
and CD86 on DCs with a high ratio of PD-L1/CD86, while 
reducing the production of pro-inflammatory cytokines, such 
as IL-12 and IL-23, and increasing that of TGF-β and IL-10. 
Moreover, VitD3 favored Treg development and blocked B-cell 
proliferation and differentiation toward antibody-producing 
plasma cells (112).
Inhibitors of the mammalian target of rapamycine (mTOR) 
pathway engage FK506-binding protein 12 forming a complex 
that blocks mTOR, but not calcineurin, resulting in non-specific 
inhibition of cell cycle progression and, therefore, of T- and B-cell 
proliferation. In vitro assays, together with experimental and 
clinical data, suggest that immunosuppression based on mTOR-
inhibitors may favor the induction of peripheral tolerance. In 
rodent models, the adoptive transfer of rapamycin-conditioned 
alloantigen-pulsed DCs resulted in prolonged cardiac and skin 
allograft survival (87, 113). Moreover, rapamycin was shown to 
facilitate peripheral deletion of alloreactive Teff by promoting 
activation-induced cell death in experimental transplantation 
models, while selectively expanding human Foxp3+ Treg and Tr1 
cells both in vitro and in vivo (114–117).
Various other immunosuppressive drugs and biologic agents 
were described to generate tolDCs in vitro including mycophe-
nolic acid (MPA) formulations (90, 118), deoxyspergualin (DSG) 
and its analogs (93), aspirin (98, 99), retinoic acid (117), and 
prostaglandin E2 (119). These substances mainly interfere with 
NF-κB pathway-mediated DCs maturation and the capacity of 
DCs to produce IL-12p70 (84, 85).
Bone marrow-derived DCs exposed in  vitro to the immu-
nomodulatory cytokines IL-10, TGF-β, or low-dose GM-CSF in 
the absence of IL-4 exhibit low expression levels of costimulatory 
molecules and pro-inflammatory cytokines with minor changes 
in MHC class-I and -II molecules. These conditioned DCs were 
less immunogenic when co-cultured with CD4+ and CD8+ 
T cells, while promoting the expansion of Treg (both natural Treg 
and iTreg) and antigen-specific T-cell hyporesponsiveness in vivo 
upon re-challenge (108, 120).
Some of these agents also directly promote the differentia-
tion of tolDCs in vivo. For example, local or systemic presence 
of cytokines such as IL-10, TGF-β, and even IFN-γ-induced 
differentiation of monocytes into tolDCs and promoted FoxP3+ 
Treg (121). The eye is a known locally immune-privileged site 
and the aqueous humor constitutively contains molecules that 
maintain DCs in an immature state, such as TGF-β2, IDO, the 
neuropeptide α-melanocyte stimulating hormone (α-MSH) and 
FasL (122). The epithelium also plays a critical role in dampening 
inflammation through the release of epithelial-derived factors, 
including prostaglandin E2, TSLP, retinoic acid, and TGF-β, 
which are able to promote tolDC (119, 123).
Cobalt protoporphyrin is an inducer of heme oxygenase 
(HO)-1, an intracellular enzyme that catalyzes the degradation 
of heme, resulting in the production of biliverdin and carbon 
monoxide. HO-1 expression is induced by local oxidative stress. 
Experimentally, HO-1 upregulation was protective in the context 
of inflammatory processes and after allogeneic SOT (124). Besides 
maintaining HO-1 expression on human DC, cobalt protopor-
phyrin prevents their maturation and promotes the secretion of 
regulatory cytokines (124, 125). Interestingly, HO-1 is also able to 
inhibit the activation of T, B, and NK cells (126).
Genetic engineering of DCs
We and others have used gene transfer technology to generate 
tolDCs via increased expression of immunomodulatory molecules 
such as IL-10, TGF-β, CTLA-4, IDO, PD-L1, or ligands for recep-
tors resulting in T-cell deletion such as CD95/Fas (TNF-family 
related death receptor) and TNF-related apoptosis-inducing 
ligand (127–129). Using gene therapy approaches, recombinant 
adenovirus vectors typically achieve great transfection efficiencies 
but are limited by pro-inflammatory effects leading to DCs matu-
ration (130). Methods using recombinant retrovirus vectors and, 
recently, non-viral gene transfer methods such as nucleoporation 
may induce lower degrees of DCs maturation (131). As an exam-
ple, genetically engineered DCs over-expressing IDO regulated 
T-cell alloresponses in  vitro, while IDO adenovirus-mediated 
gene transfer into the donor heart attenuated acute rejection of 
MHC-mismatched cardiac allografts in rats (132). Compared to 
7Obregon et al. tolDCs and Their Clinical Application
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1514
pharmacological conditioning, genetic engineering of DCs using 
retroviral or lentiviral vectors offers the advantage of a poten-
tially more stable cell phenotype and function in vivo. Another 
interesting approach that was described is the in vivo transfer of 
antigen-encoding bone marrow progenitor cells which, at steady-
state, prevent antigen-specific sensitization and promote T-cell 
tolerance mostly by deletional mechanisms (133–135).
DC exposure to apoptotic Cells
Exposure of DCs to early apoptotic cells down-modulates their 
stimulatory functions (136). DC internalization of apoptotic-
cells-associated molecular patterns selectively leads to decreased 
production of pro-inflammatory cytokines (e.g., IL-1, TNF-α, 
IL-6, and IL-12), while enhancing the secretion of IL-10 and 
TGF-β (137). This process also limits upregulation of MHC class 
II and costimulatory molecules such as CD40, CD80 and CD86, 
hence maintaining DCs in an immature state (138). This mecha-
nism contributes to self-tolerance and was exploited to induce 
tolerance to alloantigens in SOT. Following intravenous injection, 
donor allogeneic apoptotic cells were rapidly internalized in the 
spleen by red pulp macrophages and marginal zone DCs and 
were able to prolong cardiac allograft survival in rodents (139). 
Interestingly, T-cell depleting therapies used in clinical SOT, such 
as anti-CD3 or anti-CD52 monoclonal antibodies, were shown 
to induce T-cell apoptosis in  vivo. This effect was associated 
with TGF-β secretion by DCs and subsequent expansion of Treg 
(140). Thus, administration of apoptotic cells or direct induction 
of apoptosis in vivo could be used to promote the generation of 
tolDCs in vivo. Of note, the induction of apoptosis in vivo must 
be carefully controlled to prevent simultaneous activation of the 
necrotic cell death mechanism and subsequent release of necrotic 
cell-associated antigens. These antigens were demonstrated to be 
able to stimulate CD141+CD14− DCs through the Clec9A recep-
tor favoring antigen cross-presentation and, hence, CD8+ T-cell 
responses (8).
THeRaPeUTiC USe OF tolDCs  
iN aUTOiMMUNe DiSeaSeS
In Europe and North America, 5% of adults, of whom two-thirds 
are females, suffer from autoimmune diseases, the most prevalent 
pathologies being type 1 diabetes (T1D), psoriasis, RA, inflam-
matory bowel disease (IBD), and multiple sclerosis (MS).
Type 1 Diabetes
Type 1 diabetes is due to a breakdown of self-tolerance and is 
mainly orchestrated by CD4+ and CD8+ autoreactive T cells that 
activate B  cells, resulting in the production of autoantibodies 
specific for pancreatic islets β-cell antigens with progressive 
immune-mediated destruction of the β-cell mass and insulin 
insufficiency (141). Insulin treatment increases the life expectancy 
of T1D patients; however, it often fails to prevent T1D-associated 
cardiovascular and renal complications with increased morbidity 
and mortality. This opens the way to immune-based interven-
tions aiming at restoring immune tolerance and preventing early 
T1D either by targeting autoreactive T cells (142) or by modifying 
the immunogenicity of DC. As T1D is a progressive and not a 
relapsing-remitting autoimmune disease, there is only a window 
of opportunity treatment period at the onset of the disease, in 
order to reinstitute self-tolerance and preserve the function of the 
existing β-cells mass.
In non-obese diabetic (NOD) mice, GM-CSF treatment pre-
vented the development of diabetes primarily by inducing tolDCs 
and Treg (143). Another therapeutic option for T1D consists of 
transplantation of pancreatic islets or whole pancreas; however, 
such approaches require long-term immunosuppression to pre-
vent allograft rejection and reoccurrence of autoimmunity. In an 
experimental model of syngeneic pancreatic islets transplantation 
in NOD mice, both transient TGF-β expression within islets and 
transplantation of islets grafts containing TGF-β-conditioned 
tolDCs reduced the activation of islet autoantigen-specific T cells 
in graft-draining LNs, resulting in prolonged graft survival (144). 
These results support the notion that TGF-β-induced tolDCs 
could be an effective strategy to restore peripheral tolerance 
within the context of an established autoimmune disease. Aside 
from generating tolDC, TGF-β promoted the survival of thymic-
derived Treg and the differentiation of iTreg (64, 145, 146).
Other strategies using tolDCs for the prevention or treatment 
of T1D currently are being explored in experimental models. 
Antisense oligonucleotides have been used to specifically down-
regulate costimulatory molecules, resulting in DCs with an 
immature phenotype. A single injection of bone marrow-derived 
DCs engineered ex vivo with a mixture of antisense oligonucleo-
tides targeting the CD40, CD80, and CD86 primary transcripts 
significantly delayed the onset of diabetes in syngeneic NOD 
recipients. The beneficial effect of these tolDCs was partly medi-
ated by an increase in Treg (147). Based on these encouraging 
experimental data, efforts have been made at translating the use 
of autologous tolDCs in patients with new-onset T1D, aiming to 
prevent disease progression, or even to revert established disease 
(148, 149). A phase I clinical study showed that intradermal 
injection of autologous monocyte-derived costimulation-
impaired tolDCs (10 ×  106 cells every 2  weeks for a total of 4 
administrations), treated ex vivo with antisense oligonucleotides, 
was safe and well tolerated in patients with established T1D 
(150). A phase II follow-up clinical trial (ClinicalTrials.gov 
identifier NCT02354911) using DCs isolated from patients with 
recent-onset T1D is ongoing. Potential therapeutic success will 
be evaluated through the improvement of the glycemic control 
as evidence for a preserved β-cell mass. A similar clinical study 
using costimulation-impaired tolDCs is currently registered 
(identifier NCT01947569). This clinical trial includes a sequen-
tial open-label, phase-IB safety assessment and a randomized, 
double-blind, phase-IIA efficacy trial aiming at maintaining and 
improving residual β-cell function in new-onset T1D patients.
Psoriasis
Psoriasis is a chronic inflammatory skin disease mainly chara-
cterized by abnormal keratinocyte proliferation and differentia-
tion causing thickening of the epidermis (151). The psoriatic skin 
shows a prominent infiltration of neutrophils in the epidermis, 
together with macrophages, DCs, and T cells in the dermis. The 
successful use of cyclosporine A, a drug that inhibits early T-cell 
activation by blocking the TCR-downstream calcium–calcineurin 
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pathway, highlights the role of T  cells in the pathogenesis of 
the disease (152). Psoriasis has been associated with impaired 
Treg suppressive functions, resulting in overproduction of 
pro-inflammatory cytokines such as TNF-α and IFN-γ, as well 
as IL-17 and IL-22 produced by Th1 and Th17 effector cells, 
respectively (151, 153–155). The neuropeptide α-MSH is a well 
known mediator of skin pigmentation and has recently been 
shown to exert anti-inflammatory and immunomodulatory 
activities (106). Treatment with α-MSH ameliorated psoriasis-
like skin inflammation, in part by suppressing the proliferation 
and effector function of Th17 cells. The beneficial effect of α-MSH 
was shown to be mediated by tolDCs and functional iTreg (107).
Rheumatoid arthritis
Rheumatoid arthritis, an autoimmune disease associated with 
chronic joint inflammation and destruction, is characterized 
by infiltration of innate immune cells (neutrophils, monocytes, 
NK cells and DCs) as well as T and B cells in the synovial com-
partment (156). The current treatment of RA includes immuno-
suppressive drugs such as corticosteroids, cytokine antagonists 
(anti-TNF-α), costimulation blockade (CTLA-4 Ig), and B-cell 
depleting monoclonal antibodies. More recently, the potential of 
DC-mediated immunomodulation for the treatment of RA was 
investigated. Clinical-grade tolDCs have been generated from 
monocytes of patients with RA by conditioning them ex vivo 
with VitD3 and dexamethasone. The resulting tolDCs exhibited 
reduced costimulatory molecules expression, low production of 
pro-inflammatory cytokines, and impaired capacity to stimulate 
antigen-specific T  cells. Importantly, the phenotype and func-
tional characteristics of tolDCs generated from RA patients were 
comparable to those generated from healthy individuals. These 
tolDCs remained stable in the absence of immunosuppressive 
drugs even after further challenge with pro-inflammatory media-
tors (157). Interestingly, the tolDCs exhibited high cell-surface 
expression of TLR2 compared to mature immunogenic DC. 
The use of this marker should be considered in future immuno-
therapeutic protocols to assess the quality and stability of tolDCs 
produced ex vivo. An ongoing registered phase I randomized, 
placebo-controlled trial (identifier NCT01352858, AutoDECRA) 
aims to generate autologous tolDCs to be injected (single dose) 
into the knee joint of patients suffering from RA. This clinical 
study will evaluate the effect of injected tolDCs on both the local 
and the systemic disease activity.
inflammatory bowel Disease
The gut mucosa is constantly exposed to food antigens, patho-
gens, and commensal microorganisms, and holds the largest 
mass of lymphoid tissues in the body. The interplay between the 
intestinal epithelium and the local innate and adaptive immune 
system is crucial to the maintenance of immune homeostasis 
and oral tolerance. IBD (Crohn’s disease and ulcerative colitis) 
is mainly a consequence of loss of peripheral tolerance to other-
wise harmless bacterial flora with dysregulated T-cell function 
in response to local intestinal antigens (158). Current treatments 
include corticosteroids, azathioprine, and 6-mercaptopurine, 
as well as anti-TNF-α and anti-α4β7 integrin therapies in severe 
cases. T-cell activation and effector function is dependent on the 
microenvironment in which antigen presentation occurs; hence, 
tolDCs may have a potential for reestablishing intestinal immune 
regulation (159). CD103+ DCs are found in the human gut 
under normal conditions (160). These cells express low levels of 
CD40, TLR2 and TLR4, secrete IL-10 but not IL-12, and produce 
retinoic acid and IDO that promote the differentiation of iTreg 
and local immune regulation (49, 161). Peripheral tissue-resident 
pDCs exert a pivotal role in oral and mucosal tolerance (15, 16). 
An aberrant pDC distribution and effector function was described 
in the mesenteric LNs and inflamed mucosa of patients with 
Crohn’s disease compared to healthy individuals (162). Moreover, 
immature peripheral blood pDCs and cDCs were reduced during 
flares in IBD patients (163). A phase I randomized clinical study 
(identifier NCT02622763 TolDecCDintra) currently evaluates 
the safety and clinical efficacy of autologous tolerogenic ModDCs 
injected into the intestinal lesions identified by endoscopy in 
patients with refractory Crohn’s disease.
G-CSF therapy has been shown to be beneficial in Crohn’s dis-
ease patients. The benefit was associated with increased numbers 
of pDCs in the gut mucosa and induction of IL-10 production 
(164). IL-10 is a crucial immunoregulatory cytokine in the gut, 
as documented by severe spontaneous IBD in IL-10-knockout 
mice (165). Protocols are under development to produce tolDCs 
under clinical-grade conditions for IBD patients by conditioning 
ModDCs with IL-10, together with a cocktail of other cytokines 
and prostaglandin E2 (166). The generated tolDCs display a 
semi-mature phenotype (intermediate expression of CD80 
and CD86, MHC class II low), produce IL-10 with low levels 
of IL-12p70, IL-23, and TNF-α, and remain stable even in pro-
inflammatory conditions. These data suggest that the strategy 
based on using autologous DCs (derived from patients with 
autoimmune diseases) may indeed be feasible for future immune 
therapies. Although the initial monocyte population is selected 
from patients with an overt inflammatory disease, the cells can be 
conditioned to acquire beneficial tolerogenic properties ex vivo.
Multiple Sclerosis
Multiple sclerosis, a chronic inflammatory disease of the central 
nervous system (CNS), is predominantly a T-cell-mediated 
autoimmune disease characterized by leukocyte infiltration into 
the CNS, demyelination, and axonal loss. Besides current strate-
gies targeting T and/or B cells, tolDCs may represent a potential 
therapeutic approach. Myelin peptide-loaded tolDCs were gen-
erated ex vivo, exhibiting a stable semi-mature phenotype and 
an anti-inflammatory cytokine profile. These tolDCs induced 
antigen-specific hyporesponsiveness in myelin-reactive T  cells 
isolated from relapsing-remitting MS patients (167). IFN-β is an 
immunomodulatory agent used in the treatment of MS (168). 
Using healthy donors as well as MS patients PBMCs, it was shown 
that in vitro treatment with IFN-β enhanced PD-L1 expression 
on monocytes and DCs, inhibited antigen-specific CD4+ T-cell 
activation, and increased Treg numbers. In addition, serial in vivo 
measurements in MS patients before and 6 months after initia-
tion of IFN-β therapy revealed a significant increase in PD-L1 
mRNA (169). Sex hormones such as estrogens can modulate 
immune responses, contributing to the observed difference in the 
incidence of autoimmune diseases between males and females. 
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Although the overall incidence of autoimmune diseases is higher 
in women compared with men, estrogens were protective in 
the experimental autoimmune encephalomyelitis (EAE) animal 
model of MS, even during pregnancy (170, 171). In vivo exposure 
to estriol (E3), a pregnancy-specific estrogen, induced tolDCs (E3 
tolDC) characterized by increased expression of the inhibitory 
molecules PD-L1, PD-L2, B7-H3, and B7-H4, as well as media-
tors such as IL-10 and TGF-β, along with decreased expression 
of IL-12, IL-23, and IL-6. The transfer of E3 tolDCs to mice prior 
to active induction of EAE prevented the development of the dis-
ease. The protective effect was associated with immune deviation 
from pathogenic Th1/Th17  cells to a Th2 response (172). Two 
phase I clinical trials are currently registered on the ClinicalTrials.
gov website, assessing the feasibility and safety of tolDCs loaded 
with myelin peptide in patients with MS (identifier NCT02618902 
and NCT02903537). The TOLERVIT-MS (NCT02903537) trial 
involves VitD3-induced tolDCs used at increasing doses, starting 
from 5 × 106 cells. Interestingly, different routes of administra-
tion will be explored for optimal efficacy, such as intravenous, 
intradermal or direct intranodal cell injection into cervical LNs.
THeRaPeUTiC POTeNTial  
OF tolDCs iN SOT
In the absence of adequate immunosuppression after SOT, the 
recognition of donor alloantigens by recipient T  cells initiates 
a strong immune response leading to alloimmunization and 
allograft rejection. As T cells play a central role in alloresponses, 
immunosuppressive regimens have been historically developed 
to target T cells, whereas recent attention has also been devoted 
to the roles of B  cells and alloantibodies (173). The develop-
ment of immunosuppressive drugs has led to decreased rates of 
acute rejection after SOT, but their long-term administration is 
associated with side-effects including cardiovascular and renal 
toxicities, as well as infections and tumors (174, 175). Moreover, 
current regimens have limited effects on T- and B-cell memory 
responses and may interfere with the induction and expansion 
of donor-specific Treg (83, 176). Therefore, inducing sustained 
donor-specific tolerance with minimal drug exposure remains an 
important goal to improve long-term outcomes in transplanta-
tion medicine.
Compared to immune responses to autoantigens or pathogens, 
SOT constitutes a unique situation whereby DCs present antigens 
to alloreactive T  cells through three different mechanisms: the 
direct, indirect and semi-direct pathways (177). Recipient T cells 
can be activated by donor antigens either as intact allogeneic 
MHC:peptide complexes presented by donor mature DCs that 
have migrated out of the allograft (direct allorecognition) or as 
donor-derived MHC:peptide complexes that have been pro-
cessed and presented by recipient DCs (indirect allorecognition) 
(178, 179). The semi-direct pathway involves the presentation by 
recipient DCs of intact donor MHC:peptide complexes that have 
been captured from donor cell membranes or exosomes (177). 
Therefore, DCs from either donor or recipient origin can be 
considered for the development of immunotherapeutic protocols 
in SOT.
Donor-Derived tolDC
Experimental models have illustrated the potential of donor-
derived tolDCs to promote peripheral transplantation tolerance 
through the induction of donor-specific T-cell hyporespon-
siveness, deletion, and/or regulation of alloreactive T  cells 
(180–182). Costimulation-deficient tolDCs generated from 
donor bone marrow in the presence of GM-CSF, without IL-4, 
significantly prolonged the survival of MHC-mismatched heart 
allografts in mice when delivered (2 × 106 cells intravenously) 
1  week before transplantation. The effect was only partially 
antigen-specific, as third-party tolDCs also prolonged graft 
survival, albeit to a lesser extent (median graft survival time 22 
vs. 16.5 days, respectively; vs. 9.5 days in control non-treated 
mice) (180). However, in vivo maturation of the injected tolDC 
occurred, as evidenced by upregulation of CD80 and CD86, 
partially explaining the limited efficacy of tolDCs in vivo. Based 
on these results, a newer approach evaluated donor-derived 
tolDCs generated in the presence of GM-CSF and TGF-β, 
delivered in conjunction with CD40–CD40L costimulation 
blockade 1 week before transplantation. This strategy resulted 
in extended allograft survival (181). In a preclinical non-human 
primate (NHP) model, the infusion of donor-derived tolerogenic 
ModDCs (3.5–10 × 106 cells/kg) in combination with B7-CD28 
costimulation blockade (CTLA-4 Ig given at day −7 and up to 
8 weeks after transplantation) and rapamycin (started on day 
−2 and tapered over 6  months) significantly prolonged renal 
allograft survival (median graft survival time 113.5 vs. 39.5 days 
in controls) (86). In this study, tolDCs generated in vitro with 
VitD3 and IL-10 expressed low MHC class II and costimula-
tory molecules, high levels of PD-L1, and were resistant to 
inflammation-induced maturation. Ex vivo immune monitor-
ing demonstrated regulation of donor-reactive memory T cells 
in tolDC-treated NHP compared to controls. Importantly, no 
adverse events, and particularly no significant allosensitization, 
were observed in the recipients.
Donor-derived tolDCs could also contribute to the induc-
tion of donor-specific central tolerance after SOT. A recent 
study evaluated the thymus-homing ability of DCs and their 
tolerogenic function. FMS-related tyrosine kinase 3 ligand 
(Flt3L) is a cytokine that synergizes with other growth factors to 
stimulate the proliferation and differentiation of hematopoietic 
progenitor cells. Flt3L-induced bone marrow-derived DCs 
(FLDCs), but not GM-CSF-induced DCs, were able to traffic to 
recipient thymus after systemic injection. Infusion of allogeneic 
donor-derived FLDCs induced clonal deletion of both CD4 and 
CD8 single-positive alloreactive thymocytes, leading to donor-
specific central tolerance and prolonged survival of donor skin 
grafts (183).
Recipient-Derived tolDCs
It should be emphasized that the use of recipient autologous DCs 
appears to be more feasible than that of donor DCs, as tolDCs 
can be prepared from peripheral blood of the recipient before 
SOT. Recipient tolDCs could be generated and stored while the 
patient is on the waiting list, and loaded with donor-derived 
antigens (HLA peptides, donor cell lysates) at the time of trans-
plantation. Taking advantage of linked suppression mechanisms, 
Table 3 | Tolerogenic DCs (tolDCs)-based clinical trials.
NCT identifier Phase Therapeutic agent Status Sponsor/collaborators Disease
NCT00445913 I Autologous dendritic cell (DC) completed University of Pittsburgh T1DM
NCT02354911 II Autologous immunoregulatory DC Not yet recruiting DiaVacs, Inc., and others T1DM
NCT01947569 I/II Autologous co-stimulation-impaired DC Unknown DiaVacs, Inc. T1DM
NCT00434850 II Deoxyspergualin, an immunosuppressant drug, 
shown to modulate DC differentiation and function
Completed NIAID and NIDDK Islets transplantation 
in T1DM
NCT01352858 I Autologous tolDC Unknown Newcastle University and Arthritis 
Research UK
Rheumatoid arthritis 
(RA)
NCT00279461 II Vit D3 Withdrawn Indiana University RA
NCT02283671 I tolDCs loaded with myelin peptides Currently recruiting Sara Varea Multiple Sclerosis (MS) 
and Neuromyelitis 
Optica
NCT02618902 I tolDCs Not yet recruiting University Hospital, Antwerp MS
NCT02903537 I Autologous tolerogenic modDCs loaded with a 
pool of myelin peptides (tolDC-VitD3)
Not yet recruiting Fundació Institut Germans Trias i Pujol MS
NCT02622763 I Intralesional administration of tolDCs Currently recruiting Fundacion Clinic per a la Recerca 
Biomédica
Crohn’s Disease
NCT02252055 I/II Autologous tolDCs Currently recruiting Nantes University Hospital Kidney transplantation
NP, not provided; T1DM, type 1 diabetes mellitus; NIAID, National Institute of Allergy and Infectious Diseases; NIDDK, National Institute of Diabetes and Digestive and Kidney 
Diseases.
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it could be sufficient to generate recipient tolDCs expressing 
some but not all donor alloantigens (184). Importantly, the 
use of recipient DCs allows for the generation of tolDCs with 
the potential to induce indirect pathway CD4+ T-cell hypore-
sponsiveness and donor-specific Treg, while also controlling 
anti-donor humoral responses, which could have protective 
effects against chronic rejection (185–188). Recipient DCs 
pulsed with donor allopeptides and injected into the thymus 
in combination with one dose of anti-lymphocyte serum 7 days 
before transplantation induced donor-specific tolerance to 
cardiac (189) and pancreatic islets (190) allografts in rats. In an 
experimental model, the infusion of recipient DCs expressing 
donor intact MHC class I antigens selectively prevented indirect 
pathway alloreactive CD4+ T  cells activation and the generation 
of alloantibodies, resulting in long-term survival of MHC-
mismatched skin allografts (191). Interestingly, recipient bone 
marrow-derived tolDCs (generated in the presence of low-dose 
GM-CSF) infused one day before transplantation significantly 
prolonged cardiac allograft survival, even in the absence of 
prior in vitro pulsing with donor antigens. Although recipients 
showed reduced anti-donor cellular and humoral responses 
ex vivo, the effect of these tolDCs was not antigen-specific 
(192). This study suggests that, while alloantigen-specific 
immune regulation is desirable in the setting of SOT, recipient 
autologous tolDCs may also modulate the microenvironment in 
a way that favors allograft survival. The ONE study consortium 
aims at promoting clinical tolerance in living-donor renal trans-
plant recipients (193). Within this consortium, a multicenter 
phase I/II safety/efficacy trial (ClinicalTrials.gov identifier 
NCT02252055) is currently evaluating the administration of 
autologous tolDCs on top of the standard immunosuppressive 
regimen (tacrolimus-MPA-corticosteroids).
FeaSibiliTY aND SaFeTY OF DC-baSeD 
iMMUNOTHeRaPY
Phenotype and Function  
of Generated tolDCs
In recent years, an improved understanding of the mechanisms 
that govern central and peripheral immune tolerance, along 
with a more precise characterization of DC subsets, has opened 
the door to their therapeutic use in autoimmune diseases and 
SOT (Table 3). There are, however, some caveats that need to 
be addressed in order to safely translate and evaluate DC-based 
immunotherapy to the clinical arena. One major hurdle is the 
generation of high amounts of tolDCs of reproducible quality 
using clinical-grade procedures. Cells isolation, culture, and 
preconditioning protocols need to be optimized to generate 
tolDCs with stable phenotypes and functions. A better identi-
fication of subset-specific markers of human tolDCs would be 
valuable for safe delivery to patients. Another major concern is 
the stability of ex vivo generated tolDCs in a pro-inflammatory 
environment in vivo. While many studies support a maturation-
resistant state of human tolDCs produced in vitro using various 
conditioning regimens, the in vivo environment may still induce 
maturation toward undesired immunogenic DCs (180, 194, 195). 
In the context of SOT, infused donor tolDCs have been shown 
to be short-lived, being eliminated mainly by recipient NK  cells. 
Autologous recipient DCs could then process and present donor-
derived MHC:peptide alloantigens in an immunogenic context, 
leading to allosensitization and accelerated allograft rejection 
(196). However, this aspect remains controversial as there is 
evidence suggesting that, while donor tolDCs indeed rapidly 
die after infusion and are re-processed by splenic recipient DC, 
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this may not lead to allograft rejection because alloantigens are 
delivered in the context of tolDCs (197). Nonetheless, tolDC-
based “negative vaccination” most likely will need to be com-
bined with immunomodulatory drugs in vivo to harness strong 
immune activation, as demonstrated in NHP transplantation 
models (86, 198). Overall, additional preclinical and clinical 
trials are now needed to demonstrate the feasibility and safety 
of tolDC-based immunotherapy in humans. For instance, in a 
clinical study antigen-loaded autologous tolDCs were injected 
intradermic in healthy volunteers. While the treatment was well 
tolerated, it also resulted in antigen-specific regulation of Teff 
(199, 200).
Source of DCs and administration 
Protocols
The source of DCs is a central aspect of tolDC-based strategies. 
In the context of autoimmunity or end-stage organ disease, a 
possible effect of the disease on DCs population and function 
needs to be addressed. Specifically, it must be demonstrated 
that autologous tolDCs from patients are as stable as tolDCs 
derived from healthy individuals (157). The number of cells 
to be delivered, the most appropriate timing of injection, and 
the route of administration also need to be carefully evaluated. 
Antigen-specificity of DC-based immunomodulation is another 
open issue with respect to clinical applications. Targeted regula-
tion of antigen-specific T-cell responses would avoid generalized 
immunosuppression and impaired immune surveillance leading 
to infections or the development of malignancies. However, 
specific autoantigens that are responsible for T-cell priming have 
not been identified in some autoimmune diseases such as IBD, 
and peripheral DCs used for immunotherapy may not present 
some tissue-specific antigens. It also should be considered that, 
in deceased donor SOT, donor alloantigens are not known until 
the day of transplantation.
In an attempt to limit the workload and costs of ex vivo 
generation of tolDCs, while also circumventing the uncertainty 
regarding their stability, these cells could be directly generated 
in  vivo. As discussed, the administration of apoptotic cells or 
in vivo induction of apoptosis could be a first option in this regard 
(136, 201). Another possibility may involve the administration 
of specific immunomodulatory cytokines or drugs. Infliximab, a 
chimeric monoclonal antibody that neutralizes both soluble and 
membrane-bound TNF-α, is an effective treatment in autoim-
mune diseases such as psoriasis, RA and IBD, which can lead 
to long-term remission. Besides its inhibitory effects on T-cell 
activation and homing, infliximab was shown to impair the 
differentiation and antigen-presenting capacity of ModDCs 
(202) and to restore the suppressive function of previously com-
promised Treg in patients with RA (203). CTLA-4 Ig, a fusion 
protein that blocks B7-CD28 costimulation and is currently 
used in RA patients as well as in SOT, can also promote tolDC 
(204, 205). The combination of adoptive transfer of tolDCs and 
CTLA-4 Ig resulted in extended survival of MHC-mismatched 
heart allografts in mice (206). In an experimental model, CTLA-4 
Ig suppressed collagen-induced arthritis by inducing tolDCs 
and expanding Treg. This effect was abrogated by anti-TGF-β 
treatment (207). Other drugs that can be used to modulate DCs 
functions are listed in Table 2. Finally, antigens could be directly 
delivered to steady-state quiescent DCs in  vivo by specifically 
targeting DC-restricted endocytic receptors (DEC-205) with 
monoclonal antibodies (208), aiming at inducing antigen-specific 
T-cell hyporesponsiveness. Altogether, it will be important to 
take advantage of some currently used drugs or biological agents 
in order to promote an environment that favors tolDCs.
Overcoming Memory Responses
Based on their central role in immune activation, it is very 
tempting to consider immunotherapy using tolDCs for toler-
ance induction to specific antigens. Indeed, the type of DC 
and the cytokine microenvironment at the time of antigen 
presentation are major components in the regulation of T-cell 
responsiveness. While many in vitro and in vivo experimental 
data support the potential of tolDCs in regulating the priming 
of naïve T cells, less evidence exist regarding memory T cells. 
This is an important issue as the human immune repertoire 
harbors antigen-specific as well as cross-reactive long-lived 
memory T cells and antibodies which could represent an obsta-
cle for clinical translational of tolDCs-based immunotherapy in 
chronic autoimmune diseases as well as in SOT (209, 210). There 
are, however, some experimental and preclinical studies that 
illustrate the potential of tolDCs in controlling memory T cells 
(108, 133, 134), suggesting that tolDCs would be advantageous 
compared to Treg-based immunotherapy or more conventional 
immunosuppression that are less efficient in the presence of pre-
existing memory responses (211). In an experimental allergic 
airway disease model, tolDCs were shown to inhibit allergen-
specific memory Th2 responses and airway inflammation in 
sensitized hosts (135). In a clinically relevant NHP model of 
MHC-mismatched renal transplantation with minimal immu-
nosuppression, infusion of donor-derived tolDCs 1 week before 
transplantation prolonged allograft survival, with no evidence 
of host sensitization. This therapeutic effect was associated with 
selective attenuation of donor-reactive memory T-cell responses 
(86, 198).
Migration of tolDCs
Although significant progress has been made in the generation 
of tolDCs, the capacity of DCs to access LNs and encounter 
T  cells, as well as the survival of treated DCs remains a criti-
cal concern. It is known that immature DCs traffic poorly to 
LNs. Different approaches have been made to overcome this 
issue. Genetically engineered DCs that express CCR7 and IL-10 
showed improved migration ability to T-cell zones of second-
ary lymphoid organs and promoted prolonged heart allograft 
survival in a mouse model (212). Interestingly, in the setting of 
cancer vaccines development, the direct intra-lymphatic delivery 
approach is being evaluated in a clinical setting. DCs injected 
into a lymphatic vessel showed a prolonged half-life compared 
to DCs injected intravenously and were rapidly detected in LNs 
where they elicited a strong T-cell response (213, 214). The 
technique proved to be feasible and safe for short-term delivery 
of DCs. However, research is still needed to assess the efficacy of 
this route and the clinical relevance in the context of tolerance 
induction.
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CONClUSiON aND PeRSPeCTiveS
The field of immune regulation has become increasingly complex 
with the identification of both lymphoid and non-lymphoid 
cells that are involved in the induction and maintenance of 
immune tolerance. DCs are at the cornerstone of adaptive 
immune responses and, therefore, represent an appealing tool 
for immunoregulatory therapies in autoimmune diseases as well 
as in SOT. While extensive data have been generated in animal 
models, questions remain regarding the distribution and func-
tion of human DCs subsets in  vivo. Clinical protocols need to 
be optimized for the safe generation of tolDCs, ensuring stable 
phenotypes and immunomodulatory functions. Interestingly, 
although both exogenously transferred or in  vivo induced tolDCs 
may have a short half-life, they were shown to induce a regulatory 
environment (regulatory cell-subsets and cytokines) that could 
promote a more prolonged maintenance of peripheral tolerance 
(215). Finally, tolDCs immunotherapy has a unique potential for 
inducing antigen-specific central tolerance.
Whether or not tolDCs can maintain their function and 
regulate memory T-cell and B-cell responses in a strong inflam-
matory environment still remains to be demonstrated in more 
stringent preclinical models (209, 216, 217). In the clinical setting, 
tolDC-based therapy, therefore, may not be sufficient per  se to 
promote tolerance and may need to be used in conjunction with 
immunomodulatory drugs. While further preclinical and clinical 
studies are needed before tolDC-based immunotherapy can be 
successfully translated to the clinic, the quest for modalities to 
induce immune tolerance has clearly improved our understand-
ing of human DC biology. The production and use of tolDCs in 
the upcoming years will continue to represent a challenging and 
exciting road, which, ultimately, may improve various immune-
mediated clinical pathologies.
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